Indian pharma companies like Dr Reddy’s, Zydus, Cipla, and Sun can sustain low double-digit EPS growth over the medium term.

Zydus’ Usnoflast receives US FDA orphan drug designation to treat amyotrophic lateral sclerosis: Our Bureau, Mumbai Thursday, January 23, 2025, 12:15 Hrs [IST] Zydus, a leading, ...

Stocks like Jio Financial Services, Can Fin Homes, Seshasayee Paper, Supreme Petrochem, 5paisa Capital, ICICI Lombard General ...

Ahmedabad: Zydus, a discovery-based, global pharmaceutical company has announced that it has received approval from USFDA to ...

Jan. 15, 2025 — Scientists have come up with a drug that is a potential candidate for tackling memory deficits in the early stages of the disease in rodents. ... New Innovative Local Treatment ...

The Pharma sector outperformed in 2024, gaining 29%, driven by resilience to macro challenges, US FDA resolutions, and ...

This complaint was first surfaced by Law.com Radar, ALM's source for immediate alerting on just-filed cases in state and federal courts. Law.com Radar now offers state court coverage nationwide. Sign ...

The company's expanding product pipeline and strong fundamentals make it a compelling play in the pharmaceutical sector, the brokerage said. Share price of Zydus Lifesciences fell as much as 0.77% to ...

Brokerage firm Nomura has upgraded shares of Zydus Lifesciences Ltd. to "buy" from its earlier rating of "hold" and also raised its price target to ₹1,140 from ₹1,030 earlier. In a note on Thursday, ...

Zydus Pharmaceuticals USA Inc President & CEO Punit Patel said the relationship is a strong validation of Zydus’ strategic investments in the new drug applications portfolio. It “will set the ...

Zydus Pharmaceuticals USA Inc President & CEO Punit Patel said the relationship is a strong validation of Zydus' strategic investments in the new drug applications portfolio. It "will set the way for ...